[go: up one dir, main page]

MX2013011939A - Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae. - Google Patents

Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae.

Info

Publication number
MX2013011939A
MX2013011939A MX2013011939A MX2013011939A MX2013011939A MX 2013011939 A MX2013011939 A MX 2013011939A MX 2013011939 A MX2013011939 A MX 2013011939A MX 2013011939 A MX2013011939 A MX 2013011939A MX 2013011939 A MX2013011939 A MX 2013011939A
Authority
MX
Mexico
Prior art keywords
pilin
fusion proteins
haemophilus influenzae
influenzae protein
combination vaccines
Prior art date
Application number
MX2013011939A
Other languages
English (en)
Other versions
MX350013B (es
Inventor
Jan Poolman
Normand Blais
Steve Labbe
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2013011939A publication Critical patent/MX2013011939A/es
Publication of MX350013B publication Critical patent/MX350013B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden Proteína E y Puma A de Haemophilus influenzae. Más particularmente, la presente solicitud se refiere a proteínas de fusión y composiciones inmunogénicas que comprenden Proteína E y PilA, vacunas que comprenden estas composiciones inmunogénicas y usos terapéuticos de las mismas.
MX2013011939A 2011-04-13 2012-04-12 Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. MX350013B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13
PCT/CA2012/050236 WO2012139225A1 (en) 2011-04-13 2012-04-12 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

Publications (2)

Publication Number Publication Date
MX2013011939A true MX2013011939A (es) 2014-03-27
MX350013B MX350013B (es) 2017-08-23

Family

ID=47008755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011939A MX350013B (es) 2011-04-13 2012-04-12 Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.

Country Status (36)

Country Link
US (7) US8945577B2 (es)
EP (2) EP3321287B1 (es)
JP (1) JP6196963B2 (es)
KR (1) KR101999673B1 (es)
CN (3) CN107522788A (es)
AR (1) AR086078A1 (es)
AU (1) AU2012243412C1 (es)
BR (1) BR112013026175B1 (es)
CA (1) CA2830786C (es)
CL (1) CL2013002937A1 (es)
CO (1) CO6781540A2 (es)
CR (1) CR20130529A (es)
CY (2) CY1120319T1 (es)
DK (2) DK3321287T3 (es)
DO (1) DOP2013000235A (es)
EA (1) EA031580B1 (es)
ES (2) ES2776369T3 (es)
HR (2) HRP20180216T1 (es)
HU (2) HUE048848T2 (es)
IL (2) IL271862B (es)
LT (2) LT2707393T (es)
MA (1) MA35110B1 (es)
ME (1) ME02995B (es)
MX (1) MX350013B (es)
PE (1) PE20140986A1 (es)
PH (1) PH12013502121A1 (es)
PL (2) PL3321287T3 (es)
PT (2) PT2707393T (es)
RS (1) RS56903B1 (es)
SG (2) SG193906A1 (es)
SI (2) SI2707393T1 (es)
SM (1) SMT201800125T1 (es)
TW (1) TW201302779A (es)
UY (1) UY34017A (es)
WO (1) WO2012139225A1 (es)
ZA (1) ZA201307118B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
WO2014060383A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae.
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
PT3051957T (pt) 2013-09-30 2019-09-23 Iaf Science Holdings Ltd Produto para mastigar e processo para preparar o mesmo
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2016115522A2 (en) * 2015-01-16 2016-07-21 University Of Kentucky Research Foundation Lipid bilayer-integrated spp1 connector protein nanopore and spp1 connector protein variants for use as lipid bilayer-integrated nanopore
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
JP7426953B2 (ja) * 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
WO2020174044A1 (en) 2019-02-27 2020-09-03 Evaxion Biotech Aps Vaccines targeting h. influenzae
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022543281A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU648251B2 (en) * 1989-03-09 1994-04-21 Wyeth Holdings Corporation Vaccines for nontypable haemophilus influenzae
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
AU696338B2 (en) 1995-06-23 1998-09-10 Smithkline Beecham Biologicals (Sa) A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
ATE497004T1 (de) 1996-12-20 2011-02-15 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
BR0114403A (pt) 2000-10-02 2004-02-17 Shire Biochem Inc Polipeptìdeos de "haemophilus influenzae" que podem ser usados para fins de profilaxia, diagnóstico e/ou terapia
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
CA2531698A1 (en) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Method for assaying protein-protein interaction
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
BRPI0611534A2 (pt) * 2005-05-12 2010-09-21 Novartis Ag genes e proteìnas da brachyspira hyodysenteriae e uso das mesmas para diagnose e terapia
AU2006268780B2 (en) * 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
JP2009500037A (ja) * 2005-07-08 2009-01-08 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン
NZ565651A (en) 2005-08-10 2012-01-12 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN104436180B (zh) 2006-01-17 2021-08-31 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
MA35110B1 (fr) 2014-05-02
SG193906A1 (en) 2013-11-29
AU2012243412A1 (en) 2013-04-18
DK2707393T3 (da) 2018-01-29
CA2830786A1 (en) 2012-10-18
US20160250313A1 (en) 2016-09-01
US11198707B2 (en) 2021-12-14
NZ615328A (en) 2015-10-30
BR112013026175A2 (pt) 2016-11-29
US10023616B2 (en) 2018-07-17
PT2707393T (pt) 2018-02-09
DOP2013000235A (es) 2014-03-16
CR20130529A (es) 2014-03-05
ME02995B (me) 2018-10-20
IL271862A (en) 2020-02-27
HUE048848T2 (hu) 2020-08-28
EA031580B1 (ru) 2019-01-31
US10214569B2 (en) 2019-02-26
US20140056934A1 (en) 2014-02-27
EP2707393A4 (en) 2014-11-05
SG10201602549WA (en) 2016-05-30
EP2707393A1 (en) 2014-03-19
EA201391240A1 (ru) 2014-04-30
KR101999673B1 (ko) 2019-07-12
CN107522788A (zh) 2017-12-29
US20200331972A1 (en) 2020-10-22
CY1120319T1 (el) 2019-07-10
WO2012139225A1 (en) 2012-10-18
JP6196963B2 (ja) 2017-09-13
AR086078A1 (es) 2013-11-20
CN103476799A (zh) 2013-12-25
LT2707393T (lt) 2018-03-12
ZA201307118B (en) 2022-03-30
EP3321287A1 (en) 2018-05-16
PL2707393T3 (pl) 2018-05-30
HUE036983T2 (hu) 2018-08-28
ES2776369T3 (es) 2020-07-30
SMT201800125T1 (it) 2018-05-02
UY34017A (es) 2012-11-30
EP3321287B1 (en) 2020-02-26
BR112013026175B1 (pt) 2020-05-12
CA2830786C (en) 2021-10-26
ES2658512T3 (es) 2018-03-12
HRP20180216T1 (hr) 2018-03-09
US20170029472A1 (en) 2017-02-02
US8945577B2 (en) 2015-02-03
DK3321287T3 (da) 2020-05-04
PH12013502121A1 (en) 2014-01-13
TW201302779A (zh) 2013-01-16
KR20140026483A (ko) 2014-03-05
AU2012243412C1 (en) 2015-12-10
SI2707393T1 (en) 2018-03-30
US20150175670A1 (en) 2015-06-25
RS56903B1 (sr) 2018-05-31
US20150166613A1 (en) 2015-06-18
CL2013002937A1 (es) 2014-07-25
SI3321287T1 (sl) 2020-07-31
US9409957B2 (en) 2016-08-09
PL3321287T3 (pl) 2020-07-27
US9296794B2 (en) 2016-03-29
CY1122824T1 (el) 2021-05-05
MX350013B (es) 2017-08-23
AU2012243412B2 (en) 2015-05-14
EP2707393B1 (en) 2017-12-20
JP2014512365A (ja) 2014-05-22
US20180222946A1 (en) 2018-08-09
US10730917B2 (en) 2020-08-04
CO6781540A2 (es) 2013-10-31
PE20140986A1 (es) 2014-08-20
IL271862B (en) 2022-07-01
CN107383201A (zh) 2017-11-24
LT3321287T (lt) 2020-06-10
IL228344A0 (en) 2013-12-31
PT3321287T (pt) 2020-05-22
HRP20200466T1 (hr) 2020-06-26
IL228344B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX350013B (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
ZA201503097B (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
IN2014KN03063A (es)
EP3082797A4 (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2013054199A3 (en) Cmv antigens and uses thereof
EA201590490A1 (ru) ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
GB201005625D0 (en) Immunogenic proteins and compositions
LT2717914T (lt) Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
GB201103423D0 (en) Immunogenic proteins and compositions
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
GB201017519D0 (en) Vaccines
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
WO2010150242A3 (en) Immunogenic streptococcus pneumoniae peptides and peptide-multimers
WO2012118559A3 (en) Tetravalent and mixed head bivalent dengue vaccine
WO2014033158A3 (en) Pcsk9 peptide vaccine
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX2015013808A (es) Vacuna contra garrapatas rhipicephalus.
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
EP3077512A4 (en) Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
HK1224187A1 (zh) 针对药物成瘾的疫苗组合物
GB201106162D0 (en) Combination vaccine
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection

Legal Events

Date Code Title Description
FG Grant or registration